These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 12491500)

  • 21. Postmenopausal hormone replacement therapy and breast cancer.
    Jacobs HS
    Medscape Womens Health; 2000; 5(4):E2. PubMed ID: 11109047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
    Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
    Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hormone replacement therapy in women with a history of breast cancer.
    Ylikorkala O; Metsä-Heikkilä M
    Gynecol Endocrinol; 2002 Dec; 16(6):469-78. PubMed ID: 12626034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiovascular effects of selective estrogen receptor modulators. Current perspectives].
    Simoncini T; Mannella P; Genazzani AR
    Recenti Prog Med; 2003 Feb; 94(2):51-6. PubMed ID: 12908369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SERMs in chemoprevention of breast cancer.
    Gasco M; Argusti A; Bonanni B; Decensi A
    Eur J Cancer; 2005 Sep; 41(13):1980-9. PubMed ID: 15964182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003.
    Burger H
    Climacteric; 2003 May; 6 Suppl 1():11-36. PubMed ID: 12945798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Selective estrogen receptor modulators as a new concept in preventing health risks of menopause].
    Vokrouhlická J; Pavo I; Stĕpán J
    Cas Lek Cesk; 1998 Nov; 137(22):679-85. PubMed ID: 9929934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Selective estrogen receptors modulators (SERMs): biochemistry, pharmacology, and clinical use in gynecology].
    Terán Dávila J; Teppa Garrán AD
    Ginecol Obstet Mex; 2005 Aug; 73(8):424-35. PubMed ID: 16304968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology.
    Nilsson S; Koehler KF
    Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):15-25. PubMed ID: 15667591
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone replacement therapy in postmenopausal women.
    Yasui T; Uemura H; Takikawa M; Irahara M
    J Med Invest; 2003 Aug; 50(3-4):136-45. PubMed ID: 13678382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type and duration of exogenous hormone use affects breast cancer histology.
    Kumar AS; Cureton E; Shim V; Sakata T; Moore DH; Benz CC; Esserman LJ; Hwang ES
    Ann Surg Oncol; 2007 Feb; 14(2):695-703. PubMed ID: 17103262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of SERM on breast cancer and cardiovascular disease: making a comparison between raloxifene use and hormone replacement therapy on the risks of the diseases].
    Higuchi T; Mizunuma H
    Clin Calcium; 2004 Oct; 14(10):81-4. PubMed ID: 15577136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential benefits of estrogens and progestogens on breast cancer.
    Schneider HP; Jackisch C
    Int J Fertil Womens Med; 1998; 43(6):278-85. PubMed ID: 9920536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.
    Labrie F
    Endocr Relat Cancer; 2006 Jun; 13(2):335-55. PubMed ID: 16728567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hormone replacement therapy and breast cancer].
    Dobashi K
    Gan To Kagaku Ryoho; 1999 Jun; 26(7):871-6. PubMed ID: 10396312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease.
    Koledova VV; Khalil RA
    Expert Rev Cardiovasc Ther; 2007 Jul; 5(4):777-89. PubMed ID: 17605655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Estrogen replacement therapy: for whom, why and how?].
    Rozenberg S; Neusy S; Barudy J; Fellemans C; Jahjah L
    Rev Med Brux; 2002 Sep; 23(4):A382-9. PubMed ID: 12422465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug insight: breast cancer prevention and tissue-targeted hormone replacement therapy.
    Labrie F
    Nat Clin Pract Endocrinol Metab; 2007 Aug; 3(8):584-93. PubMed ID: 17643129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.